Lilly to buy Morphic in $3B bet on inflammation drug
Eli Lilly plans to spend $3.2 billion acquiring a Massachusetts-based biotechnology company and its experimental pill for inflammatory bowel disease....
Medicine
With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease
Dive Brief: Two years after canceling an initial public offering, Artiva Biotherapeutics has filed a new proposal centered around plans...
UniQure, with sale of plant, outsources Hemgenix manufacturing
Dive Brief: UniQure will sell a gene therapy production plant in Lexington, Massachusetts, to contract manufacturer Genezen in a deal...
Cartesian data add to progress, questions for CAR-T in autoimmune disease
Dive Brief: Cartesian Therapeutics on Tuesday said an experimental cell therapy it's developing succeeded in a mid-stage clinical trial of...
5 FDA decisions to watch in the third quarter
Two of last year’s largest biotechnology company acquisitions centered on a new type of treatment for schizophrenia. By the end...
Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
Today, a brief rundown of news from Beacon Therapeutics and Regeneron Pharmaceuticals, as well as updates from Vertex Pharmaceuticals, Johnson...
CureVac cuts jobs, licenses out vaccines to GSK
Dive Brief: CureVac, a specialist in messenger RNA-based therapies, disclosed Wednesday plans to lay off 30% of its workforce as...
Moderna gets US funding for bird flu vaccine development
The U.S. government has awarded $176 million to vaccine maker Moderna for development of an mRNA-based influenza shot. The funding...
Lilly drug for Alzheimer’s approved by FDA
The Food and Drug Administration on Tuesday approved a new Alzheimer’s disease drug from Eli Lilly, several weeks after a...
Eli Lilly inks another radiopharma deal, gaining option to buy startup
Dive Brief: Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option...
Eisai and Bristol Myers cancel cancer ADC deal
Dive Brief: Eisai and Bristol Myers Squibb will cancel a collaboration on a dual-acting drug being developed to treat lung...
These microscopic tunnels are a goldmine for new medicines
After months of searching, the drug hunters had tracked down the prized game they believed could help launch the next...
Alumis cuts IPO size, but nets $250M for immune drug work
Immune drug developer Alumis has raised $210 million in one of the biotechnology sector’s largest initial public offerings this year....
Supreme Court overturns Chevron doctrine, limiting reach of federal agencies
Dive Brief: The U.S. Supreme Court overturned the Chevron doctrine on Friday in a decision that could dramatically limit federal...
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
Today, a brief rundown of news from PTC Therapeutics, Esperion Therapeutics and Coherus Biosciences, as well as updates from Sanofi,...
Rocket gene therapy rejected by FDA over manufacturing
Dive Brief: The Food and Drug Administration has rejected a gene therapy developed by Rocket Pharmaceuticals for a rare type...
Merck’s pneumococcal vaccine gets CDC panel backing
Dive Brief: Advisers to the Centers for Disease Control and Prevention on Thursday unanimously recommended Merck & Co.’s recently approved...
2seventy slims down with sale of hemophilia assets to Novo
Dive Brief: 2seventy Bio is shrinking further, announcing Thursday the sale of a hemophilia A research program, along with associated...
RSV vaccine makers’ shares fall as CDC adjusts shot guidance
Dive Brief: Shares of Moderna, Pfizer and GSK fell as advisers to the Centers for Disease Control and Prevention discussed...
Novo nixes trial of blood pressure drug it bought in deal worth $1.3B
Dive Brief: Novo Nordisk will end a Phase 3 clinical trial of a hypertension drug it bought for up to...
Women with a common hormonal disorder have few good treatment options. Could GLP-1 drugs help?
Ozempic and GLP-1 drugs like it became household names due to their potent weight loss benefits, and are now proving...
Wave, with new data, plots path forward for Huntington’s drug
Dive Brief: Wave Life Sciences on Tuesday said it will meet with regulators to discuss what kind of evidence would...
Novo to spend $4B on US plant, adding to obesity drug production push
Dive Brief: Novo Nordisk will spend $4.1 billion to build a new U.S. factory in North Carolina, the latest multibillion-dollar...
Novo fills in positive picture for preventive hemophilia drug
Dive Brief: Novo Nordisk on Sunday disclosed detailed clinical trial results for an experimental hemophilia treatment dubbed Mim8, showing once-weekly...
Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data
Today, a brief rundown of news from Altimmune, Jiangsu Hengrui, Eli Lilly and others that you might have missed from over...
Amazon expands drug subscription program to Medicare members
Dive Brief: Amazon has expanded its generic drug savings program to Prime members on Medicare, throwing open the program’s doors...
Twice-yearly shots of Gilead HIV drug effective in large prevention study
Dive Brief: Twice-yearly shots of a Gilead Sciences HIV drug were so effective at preventing infections in a large late-stage...
Obesity drug from Zealand shows potential in early trial
An experimental weight loss shot developed by Denmark-based Zealand Pharma helped people with obesity lose as much as 9% of...
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
Today, a brief rundown of news from Jazz Pharma, Vanda Pharmaceuticals, ITM, Ashibio and Novartis that you might have missed...
Duchenne approval exposes FDA rift over Sarepta gene therapy
Peter Marks is again at the center of a controversial Food and Drug Administration decision on a gene therapy for...
Sarepta Duchenne gene therapy wins broader use from FDA
The Food and Drug Administration has substantially loosened limits on the first gene therapy for Duchenne muscular dystrophy in a...
FDA lifts hold on PTC Huntington’s disease trial
Dive Brief: PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the...
Roche partners with RNA editing biotech Ascidian
Roche has partnered with Ascidian Therapeutics to develop so-called “RNA exon editing” drugs, the latest foray by the Swiss pharmaceutical...
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
Today, a brief rundown of news from Belharra Therapeutics, AstraZeneca, Regenxbio and Tasyha Gene Therapies. Sanofi will work with biotechnology...
Intra-Cellular depression drug succeeds in second late-stage study
Dive Brief: Intra-Cellular Therapies plans to seek clearance to sell its medicine Caplyta for patients with depression after a second-late...
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
Dive Brief: The Food and Drug Administration on Monday approved a new vaccine from Merck & Co. that protects against...
Takeda drug for rare types of epilepsy misses goal in late-stage trial
Dive Brief: An experimental pill developed by Takeda to treat the rare epilepsies Dravet and Lennox-Gastaut syndromes missed the main...
AbbVie joins in latest gastrointestinal drug chase
AbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate...
Moderna says next-gen COVID shot effective in study
Dive Brief: Moderna said its next-generation COVID-19 vaccine succeeded in a Phase 3 study, offering increased effectiveness for adults. The...
Supreme Court preserves access to abortion pill in unanimous ruling
The Supreme Court on Thursday unanimously ruled an anti-abortion group contesting the Food and Drug Administration’s approval of the abortion...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
Dive Brief: Flagship Pioneering will partner with biotechnology startup ProFound Therapeutics to search for promising drug candidates for obesity that...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
Pfizer’s experimental gene therapy for Duchenne muscular dystrophy didn’t improve the motor function of young boys enrolled in a late-stage...
Ipsen drug for rare liver disease approved by FDA
Dive Brief: The Food and Drug Administration on Monday cleared a new treatment option for the rare liver disease primary...
Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
Approval of Eli Lilly’s experimental Alzheimer’s disease drug donanemab would help drive sales of Eisai and Biogen’s rival medicine Leqembi,...
Moderna says combination flu, COVID shot succeeds in study
Dive Brief: Moderna on Monday said a combination flu and COVID-19 shot it’s developing met the goal of a late-stage...
Lilly Alzheimer’s drug gets unanimous backing of FDA panel
An experimental and closely watched medicine for Alzheimer’s disease is one step closer to approval, after receiving support from a...
Health economics and outcomes research: Biopharma and the shift to value-based care
As healthcare moves toward the shared goal of improving patient care more economically, stakeholders across the healthcare ecosystem are increasingly...
Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
Dive Brief: Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestlé Health Science as it...
FDA advisers back updating COVID shots to target JN.1 virus family
A group of advisers to the Food and Drug Administration on Wednesday unanimously recommended that COVID-19 vaccines be updated to...
As biotech recovers, venture firms’ preferences appear to shift
After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one,...
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO
Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San...
After ‘sobering’ FDA panel, psychedelics supporters wonder what’s next
Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained...
In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection
Dive Brief: Expert advisers to the Food and Drug Administration will need to weigh whether Eli Lilly’s experimental Alzheimer’s disease...
GSK acquires oligonucleotide drug startup Elsie
Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. British drugmaker...
Lilly CFO leaves to join Alphabet
Dive Brief: Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior...
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
Today, a brief rundown of news from Eli Lilly, Cytokinetics and AbbVie, as well as updates from Gilead and the...
Illumina board approves Grail spinoff
Dive Brief: Illumina’s board of directors has approved a spinoff of Grail, targeting June 24 as the date the cancer...
FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns
Medical experts who advise the Food and Drug Administration are not convinced MDMA is ready for general use to help...
Structure pill leads to competitive weight loss in obesity study
Dive Brief: An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months,...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what...
A true liquid biopsy hub – Menarini Silicon Biosystem
Liquid biopsy has emerged as a revolutionary tool for clinical trials, offering cellular and cell-free methods that provide valuable insights...
With new Enhertu data, an ADC could overtake chemo in breast cancer
Two years ago, a drug called Enhertu changed the way doctors thought about treating an aggressive form of breast cancer,...
Gilead’s Trodelvy misses goal in bladder cancer study
An accelerated approval for Gilead Sciences’ cancer drug Trodelvy could be in question after the company disclosed Thursday afternoon that a...
Moderna wins FDA approval for RSV vaccine
The Food and Drug Administration on Friday approved a third vaccine for respiratory syncytial virus, clearing a shot from biotechnology...
FDA delays decision on Dupixent in COPD; Summit makes a bold claim
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what...
FDA staff outline shortcomings of Lykos data for MDMA therapy
Food and Drug Administration scientists have reservations about a potential new treatment for post-traumatic stress disorder that’s currently up for...
Otsuka defies digital health downturn with new company
Otsuka America, a subsidiary of the Japanese drug and device maker, this month launched a new company focused on digital...
Immunovant changes up plans for closely watched autoimmune drugs
Dive Brief: Immunovant told investors Wednesday that it’s shifting resources to focus on a less advanced experimental autoimmune disease treatment...
Merck to buy eye drug developer for $1.3B
Dive Brief: Merck & Co. on Wednesday said it has agreed to buy privately held eye drug developer EyeBio for...
A biotech working on a new approach to IVF raises $33M in fresh funding
Dive Brief: Gameto, a biotechnology company developing new treatments for fertility, has raised $33 million in venture capital funding to...
Agios cashes in on cancer drug again with $905M Royalty Pharma deal
Dive Brief: Agios Pharmaceuticals has agreed to sell to Royalty Pharma rights to royalties on a brain cancer drug it...
Insmed shares double as lung drug data convince Wall Street
New Jersey-based drugmaker Insmed gained more than $3 billion in market value Tuesday after reporting clinical trial results for an...
The future of medicine: AI’s role in uncovering new drugs
Artificial intelligence (AI) has sparked a revolution in the pharmaceutical industry, reshaping the way we approach complex biological challenges. “From...
Regeneron faces new biosimilar threats; an AI biotech lays off staff
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what...
Cytokinetics secures up to $575M in royalty deal, frustrating investors
Dive Brief: Shares in Cytokinetics sank by about one-fifth Thursday on news of a funding deal the biotechnology company struck...
Merck KGaA to buy gene therapy tools maker for $600M
Dive Brief: German drugmaker Merck KGaA agreed to buy Mirus Bio for $600 million to build expertise in a critical...
ASCO24: An early look at cancer drug study results
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what...
Lilly to pour $5B more into expanding Zepbound, Mounjaro production
Eli Lilly plans to spend another $5.3 billion building production capacity for its popular obesity and diabetes drugs, responding to...
With Duchenne decision ahead, FDA’s Marks pushes for speedy gene therapy approvals
A top Food and Drug Administration official on Friday again advocated for the speedy approval of gene therapies for rare...
Certain menopausal hormone therapy could raise ovarian cancer risk, study finds
An older form of hormone therapy taken to ease the symptoms of menopause could increase the risk of ovarian cancer,...
Orna, a circular RNA specialist, acquires a buzzy startup
Orna Therapeutics, a young biotechnology company focused on a flashy area of genetic research, is expanding through the acquisition of...
Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B
Dive Brief: Biogen is scooping up a closely held immunology startup to bring more diversity to a pipeline best known...
Pfizer expands cost cuts with new $1.5B target
Pfizer, already in the midst of an aggressive effort to trim spending, on Wednesday disclosed new plans to cut at...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
Dive Brief: AstraZeneca’s plan to reach $80 billion in sales by 2030 relies heavily on a slate of roughly one...
Lilly partners with Aktis, deepening radiopharma investment
Eli Lilly is partnering with biotechnology company Aktis Oncology to develop radiopharmaceuticals for cancer, agreeing to a deal that will...
Pheon rides wave of ADC interest with $120M financing
British biotechnology startup Pheon Therapeutics has raised another $120 million in venture funding, riding a wave of investor interest in...
Forbion-backed biotech Progentos debuts with $65M for MS drug
Forbion, a well-known backer of life sciences startups, is leading an investment round for a newly launched biotechnology company focused...
J&J to buy Proteologix and its dual-targeting antibody drugs for $850M
Dive Brief: Johnson & Johnson agreed to buy biotechnology startup Proteologix for $850 million in cash, gaining a portfolio of...
Biogen, Ionis shelve ALS drug following study failure
Biogen and Ionis Pharmaceuticals are stopping development of an experimental drug for ALS following new clinical trial results that didn’t...
Roche keeps pace in obesity drug field with early study data
Dive Brief: An experimental Roche drug helped people with obesity lose an average of nearly 19% of their body weight...
Lilly’s once-weekly insulin matches daily shots in late-stage tests
A once-weekly form of insulin being developed by Eli Lilly proved just as effective at controlling blood sugar in adults...
Erasca restructures; Novartis moves to complete MorphoSys deal
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what...
FDA approves Amgen drug for tough-to-treat form of lung cancer
Dive Brief: The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to...
Detailed trial data show Bayer drug alleviates menopause symptoms
New data from two late-stage studies of an experimental Bayer drug show it reduced the frequency and severity of common...
Investors put $400M into biotech licensing obesity drugs from China
Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss...
Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate
San Francisco-based Bolt Biotherapeutics on Tuesday said it is ending development of its lead cancer drug, laying off half its...
Eisai sets new revenue target for Alzheimer’s drug Leqembi
One of the developers behind the Alzheimer’s disease drug Leqembi has set new revenue expectations that some analysts see as...
FogPharma, Artbio join forces to design a different radiopharma drug
FogPharma and Artbio, two buzzy biotechnology companies, are betting they can combine their respective technologies to design a new type...
Bayer details layoffs as company shake-up continues
German pharmaceutical company Bayer eliminated 1,500 roles during the first three months of the year as part of a company...
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:...
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
Takeda Pharmaceutical is betting potentially billions of dollars on drugs designed to slow Alzheimer’s disease by harnessing the immune system....
Regeneron gene therapy improves hearing in two children
Dive Brief: A profoundly deaf baby who received Regeneron’s experimental gene therapy was able to hear normally within six months,...
Novo taps another Flagship startup in search for next obesity drugs
Novo Nordisk is again turning to a Flagship Pioneering startup to find new weight loss drugs, announcing on Thursday a...
Novavax gets a lifeline with Sanofi vaccine pact
Dive Brief: Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company...
Maze lands new partner for Pompe drug, after Sanofi pact came apart
Dive Brief: Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi, five months after a challenge from...
FDA delays decision on Moderna RSV vaccine
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory...
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what...
Royalty Pharma pays startup $525M for stake in Sanofi MS drug
Dive Brief: Royalty Pharma will pay biotechnology startup ImmuNext $525 million for the right to earn royalties and milestone payments...
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
Dive Brief: Takeda plans to simplify how its workforce is organized, cut spending and slim down its drug pipeline in...
AstraZeneca withdraws COVID-19 vaccine, citing declining demand
Dive Brief: AstraZeneca will no longer manufacture or supply its COVID-19 vaccine Vaxzevria, announcing Tuesday it is voluntarily withdrawing the shot...
Drug patents protect pharma profits. Track when they’ll expire here.
Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The...
Patient dies in Pfizer study of Duchenne gene therapy
A young boy enrolled in a clinical trial testing an experimental Pfizer gene therapy for Duchenne muscular dystrophy has died,...
Verve moves forward with backup base editing therapy
Dive Brief: Verve Therapeutics has treated the first participant in a recently begun clinical trial of the company’s backup gene...
Bluebird preps for first commercial use of sickle cell gene therapy
Physicians at Children’s National Hospital in Washington, D.C., last week collected the stem cells of a young boy with sickle...
Gossamer sells rights to drug it hopes can rival a new Merck therapy
Gossamer Bio has sold rights to an experimental drug that could rival a new medicine from Merck & Co., in...
BridgeBio spinout launches with $200M for KRAS cancer drugs
Dive Brief: A group of well-known biotechnology investors is putting $200 million into a newly launched spinout of BridgeBio Pharma...
Delphia starts up with $67M to make a new type of cancer drug
Cancer research is always evolving, as scientists search for ways to combat the tricks tumors use to evade drug therapies....
Moderna ends gene editing alliance with Metagenomi
Dive Brief: The gene editing company Metagenomi, which went public earlier this year, said a development partnership struck with Moderna...
CG follows big IPO with new results for bladder cancer drug
Dive Brief: An experimental drug from CG Oncology has driven bladder cancers into remission in about three-quarters of people who...
Why selling to Novartis made sense for Mariana
Mariana Oncology arrived at the J.P. Morgan Healthcare Conference this past January with momentum. The radiopharmaceutical drug developer had secured...
Amgen shares soar as executives outline obesity drug push
Dive Brief: Amgen shares soared by double digits Friday following its announcement an obesity drug it’s developing has shown enough...
Novartis to buy Mariana Oncology in radiopharmaceutical expansion
Dive Brief: Novartis is expanding its pipeline of radiopharmaceutical drugs, announcing Thursday it has agreed to pay $1 billion to...
Novo sees Wegovy sales dip on lower price, tight supply
Dive Brief: Sales of Novo Nordisk’s obesity drug Wegovy slowed over the first three months of 2024, compared to the...
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
Pfizer’s rare disease drug Vyndaqel may be its least well known blockbuster medicine. The pharmaceutical company’s COVID-19 vaccine became a...
GSK raises forecasts on strong vaccine, HIV drug sales
Dive Brief: GSK on Wednesday raised its financial forecasts for the year following strong quarterly sales of its vaccines and...
FDA defends lab test rule, as critics fear industry upheaval
Federal officials said a new rule expanding regulatory oversight of laboratory-developed tests will protect patients from inaccurate results while maintaining...
Lilly counts on manufacturing scale-up to unstick obesity drug supply
Eli Lilly expects that, by the second half of this year, it will be able to manufacture at least 50%...
Prime gets FDA green light to begin first trial test of ‘prime editing’
Dive Brief: Prime Medicine will soon begin the first clinical trial of a new drugmaking technique known as prime editing,...
FDA finalizes lab developed test rule over industry opposition
Dive Brief: The Food and Drug Administration on Monday released a final rule strengthening its authority over laboratory developed tests,...
Biogen to invest more in launch of Alzheimer’s drug Leqembi
Biogen plans to increase the number of salespeople selling the company’s prized drug for Alzheimer’s disease, now that some of...
Biogen sees ‘encouraging’ trends for postpartum depression drug
Dive Brief: Biogen has seen “encouraging early trends” in the launch of its postpartum depression pill Zurzuvae, revealing in first...
Regeneron expands in gene editing with Mammoth deal
Dive Brief: Regeneron Pharmaceuticals is upping its investment in genetic medicine, announcing Thursday a $100 million deal with CRISPR drug...
Bristol Myers to cut 6% of workforce, trim drug pipeline
Bristol Myers Squibb will cut 6% of its workforce in a restructuring meant to save $1.5 billion in costs by...
Pfizer hemophilia gene therapy arrives in US to uncertain future
Dive Brief: The Food and Drug Administration on Friday approved a new gene therapy for hemophilia, clearing Pfizer’s Beqvez for...
AbbVie tries to reassure investors on Humira biosimilar threat
Dive Brief: U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8...
BioMarin drops drug programs in pipeline cull
Dive Brief: BioMarin on Wednesday said it’s wrapped up a pipeline review and will stop investing in four experimental therapies...
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
AstraZeneca’s revenue and profits grew at a rapid clip over the first three months of the year, beating Wall Street...
Biogen: Don’t expect any big acquisitions this year
Investors who had hoped Biogen would do another flashy deal this year may not want to hold their breath, as...
Moderna turns to AI to change how its employees work
Moderna is betting big on bespoke artificial intelligence assistants. The biotechnology company on Wednesday said it has expanded a partnership...
Novartis raises forecasts as top drug sales beat Wall Street estimates
Sales of Novartis drugs for heart failure, psoriasis and multiple sclerosis were stronger over the first three months of the...
Former Bristol Myers CEO tapped as Novartis’ next board chair
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which...
Lilly to buy injectable drug plant in manufacturing ramp-up
Dive Brief: Eli Lilly on Monday said it will acquire a drug plant from Nexus Pharmaceuticals to expand its manufacturing...
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
Dive Brief: French pharmaceutical company Ipsen will work with privately held biotechnology company Skyhawk Therapeutics to make small molecule drugs...
Canaan hires Pfizer executive, reels in $100M for biotech investing
Dive Brief: Uwe Schoenbeck, a biotech veteran who most recently was chief scientific officer at Pfizer’s innovation division, has joined...
Stelara biosimilar from Alvotech, Teva approved by FDA
Dive Brief: Alvotech and Teva on Tuesday won Food and Drug Administration approval for Selarsdi, the second biosimilar poised to...
Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo
Dive Brief: Metsera, a richly funded biotechnology startup, launched Thursday with a portfolio of weight loss drugs the company claims...
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
Cerevel Therapeutics, a biotechnology company in the midst of being acquired by AbbVie, on Thursday said a Parkinson’s disease treatment...
Roche wins FDA OK for Alecensa in early lung cancer
The Food and Drug Administration has made a medicine from Roche the first specifically available for early treatment of lung...
Alvotech deal could heighten biosimilar pressure on Humira
Dive Brief: Alvotech and U.S. commercial partner Teva have signed a “long-term agreement” with an unspecified company to boost access...
Vertex begins bid for US approval of non-opioid painkiller
Vertex Pharmaceuticals is vying for approval of an experimental and closely watched painkiller that could become an alternative to addictive...
23andMe CEO plans to take company private
Dive Brief: 23andMe CEO Anne Wojcicki plans to take the DNA testing company private, according to a Wednesday filing with...
Sage’s cognition drug fails in Parkinson’s study
An experimental drug designed to improve brain function in people with nerve-degrading disorders has failed a mid-stage study that tested...
Lilly obesity drug shows benefit in sleep disorder study, pointing to new use
Fresh clinical trial results for Eli Lilly’s drug Zepbound point to a new use for the weight loss medicine in...
Intra-Cellular builds case for depression drug with late-stage trial win
An antipsychotic drug from Intra-Cellular Therapies appears to also work as an add-on therapy for depression, according to clinical trial...
J&J sees mixed performance from new multiple myeloma drugs
Dive Brief: Sales of Johnson & Johnson’s multiple myeloma medicine Tecvayli more than doubled in the first quarter versus the...
Neumora’s schizophrenia drug hit with clinical hold
Shares of Neumora Therapeutics fell Monday after the company disclosed a small clinical trial testing one of its experimental medicines...
Roche reports survival data for new dual-acting lymphoma drug
Dive Brief: Roche’s new dual-acting blood cancer drug Columvi combined with chemotherapy helped people with a type of lymphoma live...
New postpartum depression drugs are here. Diagnosis, treatment hurdles still stand in the way.
When Katherine Wisner began studying postpartum mental health in the 1980s, the field barely existed. Relatively little research was focused...
J&J, Rallybio partner on drug development for rare fetal condition
Dive Brief: Biotechnology company Rallybio is partnering with Johnson & Johnson, announcing a collaboration Wednesday to develop new treatments for...
Roche, Adaptimmune part ways on cell therapy research
Dive Brief: Genentech, the research subsidiary of Swiss pharmaceutical giant Roche, has decided to cut short a partnership focused on...
Biotech IPOs bounced back in first quarter, but backlog remains
Initial public offerings by biotechnology companies reached pre-pandemic levels during the first quarter, with nine drugmakers collectively raising more than...
European regulator concludes no suicide link to obesity drugs
Dive Brief: Novo Nordisk and Eli Lilly drugs to treat diabetes and obesity have no “causal association” with suicidal thoughts...
US sues Regeneron, alleging false price reporting on Eylea
The U.S. Department of Justice on Wednesday accused Regeneron of defrauding Medicare by knowingly inflating the average sales price for...
Century buys a startup, raises funding in cell therapy expansion
Dive Brief: Biotechnology company Century Therapeutics is expanding its autoimmune disease research with a pair of deals that will hand...
Vertex to buy kidney disease drugmaker Alpine for $4.9B
Dive Brief: Vertex Pharmaceuticals on Wednesday said it would buy biotechnology company Alpine Immune Sciences and its experimental kidney disease...
Novartis pauses some trials of cancer drug Kisqali to fix manufacturing
Dive Brief: Novartis will pause enrollment in certain clinical trials of its breast cancer drug Kisqali in order to meet...
Pfizer, with new study results, seeks to bring RSV shot to adults aged 18-59
Dive Brief: Pfizer on Tuesday said it plans to ask regulators to broaden the approval of its vaccine for respiratory...
PureTech launches Seaport, hoping to create Karuna 2.0
Hoping to repeat a recent success story, the biotechnology startup creator PureTech Health has launched a new company aimed at...
Private biotech funding ticks up as venture firms deploy cash
Private funding for biotechnology startups rose during the first three months of the year, suggesting some of the sector’s momentum...
Trial shows Wegovy can ease heart failure symptoms
Dive Brief: Novo Nordisk’s weight loss drug Wegovy helped people with obesity, diabetes and heart failure have fewer cardiovascular symptoms...
Diagonal starts up with $128M to make better ‘activator’ antibody drugs
Dive Brief: Diagonal Therapeutics, a biotechnology startup focused on creating antibodies that activate, rather than block, their targets, emerged from...
Amylyx to pull ALS drug from market in rare move
Amylyx Pharmaceuticals is pulling from market one of the few approved treatments for ALS. Rarely do drugmakers voluntarily withdraw products....
FDA approves new antibiotic for several hard-to-treat infections
Dive Brief: Swiss drugmaker Basilea Pharmaceutica on Wednesday won Food and Drug Administration approval for its drug Zevtera in a...
J&J to acquire Shockwave Medical for $13.1B
Johnson & Johnson has agreed to acquire Shockwave Medical for approximately $13.1 billion, the companies announced Friday morning. The deal...
Bristol Myers CAR-T therapy approved by FDA for earlier myeloma use
Dive Brief: The Food and Drug Administration has cleared Bristol Myers Squibb and 2seventy Bio’s multiple myeloma cell therapy for...
Boehringer Ingelheim to lay off staff amid biosimilar challenges
Dive Brief: Boehringer Ingelheim is laying off staff in response to sluggish adoption of its Humira biosimilar Cyltezo, a company...
Contineum prices biotech’s latest IPO, raising $110M for neuroinflammatory drugs
Contineum Therapeutics has raised $110 million in an initial public offering, the biotechnology industry’s 10th of the year, to advance...
Merck puts KRAS cancer drug competitor to the test
Dive Brief: Merck & Co. has begun a large clinical trial testing an experimental cancer drug it’s developing for tumors...
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
Dive Brief: Genmab said Wednesday it’s agreed to pay $1.8 billion for ProfoundBio, gaining access to the biotechnology startup’s technology...
Paragon’s hub-and-spoke biotech model yields another reverse merger
Dive Brief: A third biotechnology company from the startup creator Paragon Therapeutics is heading to the public markets. Paragon’s Oruka...
Roivant reveals positive immune drug data, share buyback plans
Dive Brief: An experimental drug being developed by a subsidiary of Roivant Sciences succeeded in a Phase 2 trial testing...
Acorda files for bankruptcy, reveals asset sale plan
Dive Brief: Acorda Therapeutics has filed for bankruptcy and, on Monday, announced it has reached an agreement to sell essentially...
Vertex moves kidney disease drug into late-stage testing
Dive Brief: Vertex Pharmaceuticals on Monday said it will advance an experimental kidney disease drug into Phase 3 testing and...
5 FDA decisions to watch in the second quarter
The year started well for the biotechnology industry. Steady dealmaking coupled with a rebound in initial public offerings helped lift...
FDA approves Merck lung disease drug acquired in $11B deal
The Food and Drug Administration on Tuesday approved a new Merck & Co. drug to treat pulmonary arterial hypertension. Called...
Moderna gets Blackstone backing for flu vaccine R&D
Dive Brief: Blackstone Life Sciences will invest as much as $750 million on influenza vaccine research and development by Moderna,...
Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
Two years after Art Krieg sold his last biotechnology company to Regeneron Pharmaceuticals, the scientific entrepreneur and industry veteran is...
Bristol Myers says KRAS drug succeeds in key trial
Dive Brief: Bristol Myers Squibb’s cancer pill Krazati helped people with a certain kind of non-small cell lung cancer live...
‘The heart is back,’ says Cardior CEO, as Novo’s $1B deal boosts field
When the Food and Drug Administration expanded approval of Novo Nordisk’s weight loss medicine Wegovy to also protect heart health,...
FDA approves Akebia anemia pill, two years after rejection
Dive Brief: The Food and Drug Administration has approved Akebia Therapeutics’ blood-boosting pill Vafseo for people with anemia from chronic kidney...
Gilead bets on Xilio cancer drug as biotech restructures
Dive Brief: Gilead Sciences will pay $30 million and invest another $13.5 million in Xilio Therapeutics to access an experimental...
Boundless Bio breaks IPO lull with $100M fundraise
Dive Brief: Boundless Bio, a cancer drug developer backed by Bayer and Arch Venture Partners, has raised $100 million in...
European study finds popular ALS drug ineffective
A large clinical trial has found that a drug commonly used by patients with ALS is not effective at treating...
Supreme Court weighs abortion opponents’ standing in mifepristone case
The Supreme Court on Tuesday heard legal arguments in a high-profile case involving the Food and Drug Administration’s expanded approval...
SQZ, Portal founder Armon Sharei on starting over in biotech
Armon Sharei never thought he’d build another biotechnology company. Sharei toiled for years to turn his Ph.D. research at the...
AbbVie to buy immune drug developer Landos
Dive Brief: Abbvie is expanding its pipeline of inflammatory disease drugs, announcing Monday a small deal to acquire biotechnology company...
Novo to acquire heart failure drug in $1B deal for Cardior
Dive Brief: Novo Nordisk will pay as much as $1 billion to acquire RNA drug developer Cardior and its experimental...
Orchard sets out to sell world’s priciest gene therapy
Dive Brief: Orchard Therapeutics said Wednesday it will offer a new gene therapy to children with a rare, devastating disease...
Bayer streamlines pharma leadership team amid company shakeup
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:...
Thermo Fisher, Bayer partner to develop companion diagnostics
Dive Brief: Thermo Fisher Scientific said Wednesday that it has partnered with Bayer to develop companion diagnostic assays for the...
